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ABSTRACT
Chronic Lymphocytic Leukemia (CLL) is a lymphoproliferative disorder with either 
indolent or aggressive clinical course. Current treatment regiments have significantly 
improved the overall outcomes even if higher risk subgroups - those harboring TP53 
mutations or deletions of the short arm of chromosome 17 (del17p) - remain highly 
challenging. In the present work, we identified USP7, a known de-ubiquitinase with 
multiple roles in cellular homeostasis, as a potential therapeutic target in CLL. We 
demonstrated that in primary CLL samples and in CLL cell lines USP7 is: i) over-
expressed through a mechanism involving miR-338-3p and miR-181b deregulation; 
ii) functionally activated by Casein Kinase 2 (CK2), an upstream interactor known to 
be deregulated in CLL; iii) effectively targeted by the USP7 inhibitor P5091. Treatment 
of primary CLL samples and cell lines with P5091 induces cell growth arrest and 
apoptosis, through the restoration of PTEN nuclear pool, both in TP53-wild type and 
-null environment. Importantly, PTEN acts as the main tumor suppressive mediator 
along the USP7-PTEN axis in a p53 dispensable manner. In conclusion, we propose 
USP7 as a new druggable target in CLL.
INTRODUCTION
Chronic lymphocytic leukemia (CLL) is a 
lymphoproliferative disorder with either an indolent 
clinical course and long survival time or aggressive 
behavior in a smaller proportion of cases [1-6]. Standard 
immuno-chemotherapy regimens achieve a 60-70% 
overall response rate, with only a fraction of treated 
patients obtaining a complete hematological remission, 
while the median time to treatment failure is around 
18-20 months. Unsatisfactory therapeutic options still 
exist for higher risk groups, and in particular those 
harboring TP53 mutations or deletion of the short 
arm of chromosome 17 (del17p) [7, 8]. In addition to 
chemotherapy and anti-CD20 immunotherapy, molecular 
insights into CLL pathogenesis and maintenance allowed 
to identify novel drugs to target a variety of signaling 
routes to enter the clinical arena [9]. These include PI3K 
inhibitors (e.g. idelalisib) [10], BTK inhibitors (ibrutinib, 
acalabrutinib) [11, 12] and BCL2 inhibitors (venetoclax, 
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navitoclax) [13, 14]. Del17p has been reported to be 
present in ~7% of chemo-naïve CLL cases and 20-40% 
of relapsed patients and is routinely used as a prognostic 
marker, representing the sub-population facing an unmet 
clinical need. Furthermore, idelalisib (Zydelig) [15] and 
ibrutinib (Imbruvica) [16] have been FDA-licensed for 
CLL harboring del17p following optimistic results in 
randomized controlled trials. Some of these drugs are 
directed to PI3K pathway suggesting its essential role for 
the maintenance of CLL malignant phenotype irrespective 
of TP53 status. 
Recently, Chauhan et al. showed that 
pharmacological inhibition of the de-ubiquitinase USP7 
strongly induces apoptosis in multiple myeloma cells 
resistant to conventional and bortezomib-based therapies 
[17]. USP7 promotes the de-ubiquitination of various 
targets with consequent changes in their protein levels 
and cellular compartmentalization and behaves as a central 
rheostat in the definition of cell survival. USP7 plays an 
essential role in tumorigenesis through the inactivation 
of three major tumor suppressors: p53 [18], PTEN [19, 
20] and FoxO [21]. By affecting either their cellular 
compartmentalization or adjusting their protein levels, 
USP7 influences the cellular fate, balancing survival 
and cell death. Both p53 [22] and PTEN [23-28] are 
known to play important tumor suppressive roles in CLL 
pathogenesis. In particular, while TP53 is in most cases 
genetically inactivated through point mutations or deletion 
and correlates with resistance to standard treatments and 
poor prognosis, PTEN has been shown to be functionally 
inactivated through tail-phosphorylation by the CLL 
relevant Protein Kinase 2 (CK2) [26, 27, 29, 30]. Here 
we investigate the mechanisms of USP7 regulation in 
CLL, explore the functional role of USP7 in the broader 
context of its signaling partners (i.e. the USP7-PTEN 
network) and provide evidences supporting its potential 
therapeutic exploitation. Finally, we discuss the ability of 
USP7 inhibitor to effectively target CLL cells regardless 
of their TP53 status.
RESULTS
USP7 is strongly up-regulated in CLL samples
 To assess the levels of expression of USP7 in 
CLL, real-time PCR was performed on mRNA isolated 
from primary CD19+ lymphocytes of CLL patients and 
healthy individuals. As reported in Figure 1A, USP7 
mRNA is markedly up-regulated in CLL. Similarly, using 
protein extracts from primary CD19+ lymphocytes of 
CLL patients and representative healthy individuals, we 
observed significantly increased levels of USP7 in CLL 
samples when compared to normal cells (Figure 1B). 
Most CLL patients showed a USP7/GAPDH ratio higher 
than normal CD19+ lymphocytes, indicating that USP7 
was generally over-represented in CLL (Figure 1C). The 
biological features of enrolled patients were reported in 
Supplementary Table 1. USP7 is expressed both in the 
nucleus and in the cytoplasm of representative primary 
CLL samples and CLL cell lines, MEC-1 and EHEB 
(Figure 1D), as observed in other cellular models [31-34]. 
Immunohistochemical analysis showed a strong positivity 
for USP7 in 3 out of 5 CLL samples when compared to 
normal lymphocytes in normal bone marrow specimens 
(Figure 1E). Finally, we analyzed USP7 expression levels 
in a publicly available larger cohort of CLL patients (n 
= 217) and 12 normal samples [35]. Also in this case, 
USP7 was over-expressed in CLL when compared to 
normal samples (Figure 1F). Although this cohort included 
only patients with stage A of the Binet classification (i.e. 
limited-stage disease), USP7 overexpression in CLL is 
highly significant and therefore these data suggest that 
its overexpression may represent a common feature even 
at the early stages of the disease. Altogether these data 
provide a rationale to investigate USP7 as a target in CLL. 
USP7 is regulated at post-transcriptional and 
post-translational levels
Prior to investigate USP7 as a potential therapeutic 
target in CLL, we sought to assess the mechanisms of 
USP7 overexpression and activation in CLL. Micro-RNAs 
(miRNAs) have been reported as functional players in CLL 
pathogenesis with prognostic significance [36]. Therefore, 
we performed a bioinformatic survey of publicly available 
datasets [35] returning a list of miRNAs potentially able 
to target the USP7 3′-UTR (Supplementary Figure S1A). 
The calculated Pearson correlation coefficient was highly 
significant for an inverse correlation between USP7 and 
miR-338-3p and miR-181b (Supplementary Figure S1B 
and S1C). Thereby, we firstly subcloned the miR-338-
3p responsive element (MRE) of USP7 (Supplementary 
Figure S1D, upper panel) downstream to a luciferase 
construct and a reporter assay showed that miR-338-3p 
could directly down-regulate USP7 at post-transcriptional 
level (Supplementary Figure S1D, lower panel). Similar 
data were obtained with miR-181b response element 
(Supplementary Figure S1E upper and lower panel). 
Accordingly, miR-338-3p transfection strongly reduced 
USP7 levels (Supplementary Figure S1F). We provide the 
in vitro proof of principle that USP7 overexpression in 
CLL may be sustained through miRNA deregulation, and 
in particular by miR-338-3p and miR-181b. Interestingly, 
miR-181b was already shown to be down-regulated in 
CLL and to play a role in CLL pathogenesis through the 
regulation of the oncogene Tcl1 [37, 38]. Further analyses 
are however mandatory to assess the role of miR-338-
3p and miR-181b in the setting of larger CLL cohorts, to 
better correlate their expressions with clinical outcomes 
and biological characteristics.
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Figure 1: USP7 is strongly up-regulated in CLL samples. A. Quantification of mRNA levels in 5 normal CD19+ lymphocytes 
and 19 CLL samples. *p < 0.05. B. Primary CD19+ lymphocytes from two representative normal individuals and ten CLL patients were 
analyzed for USP7 protein expression. C. Quantification of USP7/GAPDH ratio in 5 normal CD19+ lymphocytes and 19 CLL samples. **p 
< 0.01. D. Western Immunoblot of cytoplasm/nuclear fractions in CLL cell lines model and two representative primary CLL samples. E. 
USP7 immunohistochemical of human biopsies in one representative normal bone marrow and two CLL specimens. F. Box-plot of USP7 
mRNA levels in normal lymphocytes (n = 12) compared to CLL primary cells (n = 217). ****p < 0.0001. 
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Next, we studied USP7 post-translational 
modifications. In particular, it was already demonstrated 
that Protein Casein Kinase 2 (CK2) phosphorylates USP7 
on serine 18 residue with consequent regulation of protein 
stability and activation [33]. 
Despite several USP7 isoforms have been predicted 
(http://www.ncbi.nlm.nih.gov/IEB/Research/Acembly/
av.cgi?db = human&q = USP7) (Figure 2A), only 
USP7 isoform 1 contains serine 18. Due to the relevant 
biological role of CK2 in CLL pathogenesis [26, 27, 29, 
39-43], we sought to investigate whether CK2 is involved 
in modulating USP7 activity in this disease. We first 
investigated the levels of USP7 isoforms in primary CLL 
samples. Unfortunately, we were not able to specifically 
detect isoform 2. Interestingly, isoform 1 was the most 
represented variant in CLL primary samples (Figure 
2B) and in MEC-1 and EHEB CLL cell lines (Figure 2C 
and Supplementary Figure S2A). In line with previous 
results [33], we observed that USP7 is phosphorylated 
on Ser18 residue in the EHEB and MEC-1 cell lines 
and phosphorylation was reverted by CK2-inhibitor 
treatment (Supplementary Figure S2B). Notably, CK2 
inhibitor treatment did not affect total USP7 mRNA 
levels (Supplementary Figure S2C) but, as observed 
elsewhere [33], a prolonged treatment with 25 µM TBB 
for 72 hours was associated with USP7 protein reduction 
(Supplementary Figure S2D). Since these cells expressed 
mostly USP7 isoform 1, the one with serine 18, these 
data suggest that CK2 promotes USP7 stabilization in 
CLL context, through phosphorylation. On the contrary, 
CK2 inhibitors did not chance the localization of USP7 
(Supplementary Figure S2E). A kinase assay of purified 
USP7 incubated in the presence of CK2 confirmed that 
CK2 phosphorylates USP7 (Figure 2D). Finally, also 
phospho-Serine-18 specific antibody demonstrates that 
USP7 is highly phosphorylated on this residue in primary 
CLL samples (Figure 2E). Overall, our data show that 
USP7 overexpression may be correlated to miRNAs 
deregulation and that USP7 is functionally under the 
upstream control of CK2, thus enforcing the functional 
role of USP7 in CLL.
Targeting USP7 induces growth inhibition and 
apoptosis in CLL cell lines
Recently a few inhibitors have been developed to 
specifically target USP7 with promising results in different 
cancer models [17, 44-50]. USP7 inhibitor P5091 was 
shown to exhibit impressive properties for the treatment 
of Multiple Myeloma (MM) [17]. To explore the potential 
therapeutic role of USP7 inhibition in CLL, we treated 
the TP53-mutated CLL cell line MEC-1 with P5091. 
P5091 treatment was associated with: i) dose-dependent 
reduction of cell viability via p21 at a concentration as low 
as 1 µM (Figure 3A, left panel and insert) through MDM2 
(Supplementary Figure S3A and S3B), with a similar 
mechanism as described previously [17]; ii) accumulation 
in the G2/M phase of the cell cycle (Figure 3B); iii) 
inhibition of anchorage-independent growth (Figure 3C, 
upper panel and lower panel) and iv) activation of the 
apoptotic pathway as indicated by the proteolytic cleavage 
of Caspase 3 (Figure 3D upper and lower panel). Similar 
results were obtained also in the TP53-wild type EHEB 
CLL cell line (Supplementary Figure S4A and S4B). 
Interestingly, both TP53-mutated MEC-1 and TP53 wild-
type EHEB displayed a similar P5091 IC50 (MEC-1 1.3 
µM; EHEB 2 µM), implying a similar p53-independent 
“response phenotype” (Supplementary Figure S4C). 
Notably, despite being characterized by TP53 deletion, 
MEC-1 cells were highly responsive to P5091, suggesting 
that USP7 inhibition can overcome TP53 deletion-related 
resistance to apoptosis. P5091 treatment did not affect p53 
targets in MEC1 cell line (Supplementary Figure S5A) and 
PTEN levels did not change (Supplementary Figure S5B). 
 To verify the specificity of the USP7 inhibitor, we 
then used a pool of 5 different siRNAs able to efficiently 
silence USP7 (Supplementary Figure S6A). USP7 
silencing in MEC-1 cells (Figure 3E and Supplementary 
Figure S6B) abrogated cell growth, corroborating the bona 
fide data we obtained with the inhibitor. Consistently, 
USP7 silencing promoted MEC-1 apoptosis (Figure 3F). 
Collectively, these data demonstrate that USP7 targeting 
through small molecule inhibition is highly effective in 
CLL cell lines.
Lastly, we assessed whether P5091 treatment 
synergized with one of the recently approved drugs, 
idelalisib [15, 51]. We performed proliferation and 
apoptosis assays using MEC-1 and EHEB cell lines. 
Interestingly, combined treatment of MEC-1 and EHEB 
cell lines with the PI3K-delta and USP7 inhibitors 
synergistically inhibits proliferation and promotes 
apoptosis induction (Supplementary Figure S7A-S7F). 
These results suggest that USP7 inhibition may impact on 
pathways that may be PI3K/AKT independent.
USP7 inhibition affects PTEN delocalization
USP7 is a de-ubiquitinase that targets three 
major tumor suppressors: p53 [18], PTEN [19, 20] 
and FoxOs [52]. USP7 promotes the deubiquitination 
of: i) p53, increasing its stability via MDM2; ii) 
PTEN, favoring its shuttling from the nucleus into the 
cytoplasm; iii) FOXOs, favoring changes in cellular 
compartmentalization. By changing tumor suppressors’ 
cellular compartmentalization and protein levels, USP7 
plays an essential and direct role in tumorigenesis, while 
its inhibition offers the challenging therapeutic options 
to reactivate tumor suppressive functions and trigger 
cancer selective apoptotic response. Our observation that 
P5091 markedly promoted apoptosis in TP53-mutated 
MEC-1 cells suggests that P5091 effects are p53-
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Figure 2: USP7 Post-translational modifications in CLL. A. Representation of USP7 isoforms segments highlighting the only 
isoform containing serine-18. B. Quantification of USP7 isoform 1 (Iso_1) and isoform 3 (Iso_3) mRNA levels in CD19+ lymphocytes from 
19 CLL samples. **p < 0.01. C. Quantification of USP7 isoform 1 and 3 mRNA levels in MEC-1 cells. **p < 0.01. D. Kinase assay with 
purified USP7 protein and immunoprecipitated CK2. The assay was performed in the absence or presence of 60 µM TBB. p-SER: phospho-
serine. E. Upper panel: Purified tumor cells from normal CD19+ and CLL patients were analyzed for the indicated proteins. Lower panel: 
quantification of pSer18 USP7 expression level, normalized on total USP7. **p < 0.01.
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Figure 3: Targeting USP7 induces growth inhibition and apoptosis in CLL cell lines. A. Proliferation analysis of MEC-1 
cells treated with USP7 inhibitor (P5091) for the indicated times and concentrations. The number of cells at day 0 was set at 1 unit. Insert: 
lysates from control and P5091-treated MEC-1 cells were analyzed for p21 expression level. B. Cell cycle distribution of MEC-1 cells 
treated or not with P5091 for 3 days. C. Quantification and representative images of soft-agar growth assay in MEC-1 cells treated with 
the indicated concentrations of P5091 for 15 days. ***p < 0.001. D. Upper panel: evaluation of apoptosis in MEC-1 cells treated with the 
indicated concentrations of P5091 for 24 hrs. ***p < 0.001. Lower panel: cleaved-caspase-3 Western Immunoblot in the same conditions. 
E. Proliferation analysis in MEC-1 cells infected either with control (siCTR) or USP7-directed (siUSP7) siRNAs (insert). *p < 0.05; **p < 
0.01. F. Apoptosis analysis of MEC-1 cells described in E. *p < 0.05. 
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independent in CLL. Since we previously demonstrated 
that USP7 plays an essential role in the regulation of 
PTEN compartmentalization in CML [20, 34], we sought 
to investigate whether USP7 functionally inactivates 
PTEN in CLL through PTEN nuclear exclusion. PTEN 
plays a role in CLL pathogenesis where it is not mutated/
deleted [25] but functionally inhibited. Therefore, we 
speculated that USP7 inhibition may promote PTEN 
reactivation and consequently cancer selective apoptotic 
induction, without affecting normal cells. PTEN is an 
Figure 4: USP7 inhibition affects PTEN delocalization. A. PTEN-ubiquitination assay in MEC-1 cells treated with 16 μM P5091 
for 2 and 4 hours. B. USP7 Western Immunoblot upon cytosol/nuclear fractionation of MEC-1 cells treated with P5091 at a concentration 
of 16 μM for 2 and 4 hours. C. Immunofluorescence assay showing PTEN cellular compartmentalization in MEC-1 cells treated with 4.2 
μM P5091 for 24 hours. Anti-PTEN antibody (green); Propidium iodide (red). D. Proliferation analysis of MEC-1 cells expressing GFP-
PTEN-WT and GFP-PTEN-NLS. Cell growth was quantified by counting cells with trypan blue exclusion of dead cells at each time point. 
***p < 0.001. E. Percentage of apoptosis in GFP-PTEN transfected MEC-1 cells. *p < 0.05. 
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essential tumor suppressor implicated in tumorigenesis 
through either phosphatase dependent and independent 
functions [53]. In particular, it is involved in the negative 
regulation of the PI3K-AKT signaling, a major pathway 
responsible to CLL maintenance, and acts in the nucleus 
where it regulates proliferation [54] and genomic stability 
[55, 56]. As shown in Figure 4A, treatment with USP7 
inhibitor restored PTEN endogenous ubiquitination levels. 
Therefore, P5091 promoted PTEN re-localization into the 
nucleus, as detected by cell fractionation (Figure 4B) and 
immunofluorescence (Figure 4C) of MEC-1 cell line, but 
did not changed PTEN protein levels (Supplementary 
Figure S5B). Also, the inhibition of the USP7 upstream 
regulator CK2 with TBB promoted PTEN shuttling, 
therefore indicating that CK2/USP7/PTEN forms an 
important network in CLL cells (Supplementary Figure 
S8A). To confirm the tumor suppressive role of nuclear 
PTEN in CLL cells, we forced PTEN expression into the 
nucleus upon transfection with a Nuclear Localization 
Signal (NLS)-bearing PTEN construct. Nuclear PTEN 
expression was associated with growth arrest (Figure 
4D) and apoptosis induction (Figure 4E), suggesting that 
PTEN acts as a potent tumor suppressor in CLL. Our data 
demonstrate that USP7 is responsible for PTEN nuclear 
exclusion with consequent impairment of its tumor 
suppressive functions and that USP7 inhibition restores 
PTEN nuclear pool and its oncosuppressive activity in the 
context of CLL. 
P5091 affects USP7/PTEN network in primary 
CLL samples
We evaluated PTEN cellular compartmentalization 
in primary CLL samples by immunofluorescence 
and western immunoblot upon nuclear/cytoplasmic 
fractionation. Interestingly, normal CD19+ lymphocytes 
displayed a physiological localization of PTEN both 
in the nucleus and the cytosol (which we refer to as a 
“diffuse pattern”), while most of CLL CD19+ lymphocytes 
were characterized by PTEN nuclear exclusion (from 
an exclusively “cytosolic” PTEN to a “predominantly 
cytosolic” compartmentalization of PTEN) (Figure 5A 
and Supplementary Figure S9A). Although few cells in 
the control group may display cytosolic expression of 
PTEN, a fact recalling a physiological degree of dynamic 
regulation, the overall statistics across CLL lymphocytes 
clearly showed a major unbalance of the PTEN pool 
toward the cytoplasm (Figure 5B). This latter result 
confirms the relevance of these findings in human disease. 
To corroborate the results in CLL cells lines, we decided to 
test the impact of P5091 in CLL samples. Also in primary 
cells, P5091 treatment strongly promoted apoptosis 
(Figure 5C and Supplementary Figure S9B) while 
B-lymphocytes from normal individuals were unaffected. 
Only higher concentrations of P5091 (16 µM) decrease the 
viability of normal lymphocytes (Supplementary Figure 
S9C), suggesting a potential selectivity of the therapy. 
Strikingly, three TP53 deleted CLL samples were equally 
subjected to P5091 apoptosis induction, confirming 
that USP7 inhibitor acts in a p53-independent manner. 
Moreover, USP7 inhibitor treatment of primary CLL was 
associated with increased ubiquitination of endogenous 
PTEN and consequently PTEN re-localization into the 
nucleus (Figure 5D and 5E). These data demonstrated a 
potent activity of P5091 against primary CLL cells. 
DISCUSSION
Several effective drugs for the treatment of CLL 
have been recently licensed while others are in advanced 
phases of clinical development. Notwithstanding, the 
effective treatment of TP53 mutated or deleted (del17p) 
CLL patients remains challenging. TP53 mutations/
deletions are involved in CLL transformation into a more 
aggressive disease (i.e. Richter syndrome) and may reside 
in dormant clones in the very early stages of the disease 
[57]. Indeed, treatments exert a selective pressure favoring 
the expansion of TP53-mutated/deleted clones; despite 
TP53 restoration in tumors affects cancer maintenance, 
no specific therapies have been developed to effectively 
overcome TP53 mutated tumors. 
Overall, in this study we utilized CLL cell lines and 
primary tumor cells as models to investigate the USP7 
role in CLL and to demonstrate the efficacy of a small 
molecule inhibitor P5091, in this disease. As summarized 
in Figure 5F, our data show that the de-ubiquitinase USP7 
is aberrantly expressed in CLL. USP7 is over-expressed in 
about 70% of CLL CD19+ lymphocytes, both at the mRNA 
and protein levels. This observation has been originally 
made using our (single) institute cohort of CLL patients 
and extended within a previously published mRNA 
expression dataset counting 217 CLL cases [35]. It should 
be questioned that this cohort included only patients in 
the Binet A CLL stage, which represents the early stage of 
the disease. However, it should be considered that in other 
cancer types USP7 over-expression has been commonly 
correlated with both disease progression and advanced 
stages, therefore suggesting that USP7 over-expression in 
CLL may play a pathogenetic role even in the early stages 
of this disease. 
Following identification of USP7 aberrant 
expression in CLL primary cells, we investigated the 
mechanisms responsible to its deregulation. High USP7 
expression appeared to be a consequence of deregulated 
miRNA expression and/or post-translational regulation 
by CK2, an aberrantly expressed serine-kinase in CLL. 
miRNA expression profiling revealed that miR-338-3p 
and miR-181b anticorrelate with USP7 in CLL samples 
and in vitro experiments confirmed their direct interaction 
with the 3’UTR of the gene. Unluckily, due to the inability 
to demonstrate miR-338-3p down-expression in CLL 
samples versus normal individuals in this dataset, its real 
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Figure 5: P5091 affects USP7/PTEN network also in primary CLL samples. A. Left panel: Representative immunofluorescence 
images on CD19+ lymphocytes from peripheral blood of normal and CLL individuals, stained with anti-PTEN antibody (green) and 
Propidium iodide (red). Right panel: Western Immunoblot of cytoplasm/nuclear fractions in two representative primary CLL samples. B. 
Quantification of PTEN cellular compartmentalization in CD19+ lymphocytes from 5 normal and 14 CLL samples. Data represent mean 
±SD of > 50 cells analyzed from each sample and expressed as percentage. C. Apoptosis analysis of CD19+ lymphocytes from normal (n 
= 3) and CLL (n = 9) individuals treated with P5091 for 24 hours. Percentage of each sample was normalized to corresponding untreated 
condition. ***p < 0.001. D. PTEN ubiquitylation assay in CLL primary cells treated with DMSO or P5091 (16 μM) for 2 hours. E. PTEN 
cellular compartmentalization (green) in a representative PTEN nuclear-excluded CLL sample before and after treatment with P5091 (4.2 
μM) for 24 hours. F. Model of USP7 network in CLL.
Oncotarget10www.impactjournals.com/oncotarget
role in CLL pathogenesis requires further investigations. 
It could be speculated that the contribution of miR-338-3p 
in USP7 regulation is different in CLL respect to normal 
lymphocytes or that miR-338-3p is involved in CLL 
pathogenesis through different mechanisms. Conversely, 
miR-181b is already known to be downregulated in 
CLL and to play a key role in CLL pathogenesis [37, 
38]. While further analyses are mandatory to dissect the 
role of these miRNAs in the regulation of USP7 in CLL, 
our data clearly confirmed that CK2-mediated USP7 
phosphorylation enhances its de-ubiquitinase activity 
in CLL. More precisely, we found that CLL samples 
mostly expressed the serine-18 USP7 isoform and that 
CK2-mediated phosphorylation plays a key role in the 
regulation of USP7 activity and consequently of its 
targets, as demonstrated elsewhere [33]. While further 
analyses should be performed to better dissect the CK2/
USP7/PTEN network, due to the ability of CK2 to activate 
USP7 as a deubiquitinase and to directly promote PTEN 
tail phosphorylation, these findings provided the rational 
for the evaluation of USP7 inhibitor in CLL and therefore 
we focused on anti-tumor activity of its inhibitor, P5091. 
We showed that treatment with low concentrations of the 
USP7 inhibitor selectively induces apoptosis of MEC-
1 and EHEB CLL cell lines and primary CLL CD19+ 
lymphocytes, while maintaining unaffected CD19+ 
lymphocytes from normal individuals. P5091 treatment 
effectively induces apoptosis in both TP53-mutated MEC-
1 and TP53-wild-type EHEB cell lines and, remarkably, 
is highly effective in del17p CLL primary CD19+ 
lymphocytes, with an apoptotic induction ‘potency’ like 
the one observed in TP53-wild type CLL samples. 
To better evaluate the mechanisms of USP7 anti-
leukemic properties in TP53-wild-type and mutated CLL, 
we then analyzed USP7 targets in this specific context. 
USP7 was originally studied as a gene able to regulate 
p53 through a complex MDM2/p53 network. It also 
targets two major tumor suppressors: PTEN and FoxO(s). 
Specifically, USP7 induces the de-(mono)-ubiquitination 
of PTEN and FoxO, promoting their nuclear exclusion; on 
the contrary, mono-ubiquitination favors an enrichment of 
the nuclear pool. Nuclear PTEN targets cell cycle [54] and 
the machinery that regulates genomic stability [55, 56], 
thus protecting genomic integrity. PTEN was described as 
a functionally inactive tumor suppressor in CLL. Notably, 
no genetic alterations of PTEN have been reported in CLL, 
suggesting that therapies that promote PTEN reactivation 
may effectively target CLL cells. 
In line with these considerations, we have here 
observed that USP7 promotes PTEN delocalization in 
CLL samples, favoring the loss of its nuclear tumor 
suppressive functions. Conversely, USP7 inhibition is 
associated with the restoration of the PTEN nuclear pool 
and correlates with apoptosis induction and cell growth 
arrest. The functional reactivation of tumor suppressor 
PTEN can indeed by-pass the apoptotic resistance of TP53 
mutated cells/clones.
While USP7 involvement in tumorigenesis should 
be further investigated (e.g. in deep studying USP7 
targeting miRNA(s) and regulation of CK2 enzymatic 
activity), our data attribute to USP7 inhibitors a 
therapeutic role in CLL precision medicine, functioning 
through the reactivation of the tumor suppressor PTEN. 
In doing that, USP7 inhibitor P5091 activates an apoptotic 
and cell growth arrest response which occurs by-passing 
TP53 genetic loss. 
MATERIALS AND METHODS
Cells and primary human samples
Human samples were collected from n = 20 
untreated CLL patients at the San Luigi Hospital 
(Orbassano, Italy), following informed consent and with 
obscured identity; CD19+ lymphocytes were isolated from 
healthy donors (n = 5) accordingly to the MiltenyiBiotec 
protocol (MiltenyiBiotec, #130-050-301). The project 
was reviewed and approved by the institutional ethical 
committee (code #10/2013). Human MEC-1 cell line was 
gently provided by Prof. Deaglio (University of Turin) 
and was grown in IMDM medium (Life Technologies) 
containing 10% heat-inactivated fetal bovine serum (FBS, 
Sigma Aldrich), supplemented with 2 mM L-glutamine, 
100 U/ml penicillin, and 0.1 mg/ml streptomycin and 
maintained at 37°C in a 5% CO2 humidified atmosphere. 
EHEB cell line was purchased from DSMZ and was 
maintained in RPMI 10% FBS. The lymphoid nature of 
this cell line was authenticated by flow-cytometry (CD19+ 
positivity). 
TP53 status of MEC-1 and EHEB was previously 
investigated [58]. HEK293T cells were obtained from 
ATCC and were maintained in DMEM supplemented with 
10% FBS. Cell lines were regularly tested with MycoAlert 
(Lonza) to ascertain that cells were not infected with 
mycoplasma. 
Plasmids, silencing and nucleofection
 GFP and PTEN constructs were described 
elsewhere [20, 59]. Specific USP7 siRNA was purchased 
from Sigma-Aldrich (EHU-1311171). Negative Control 
siRNA from Ambion (Cat#4611G) was used as a control. 
For the transient transfection 1.5 × 106 MEC-1 cells were 
pelleted and resuspended in 100μl of Nucleofector solution 
(Lonza), according to the manufacturer’s protocol. For 
each nucleofection, 2 μg of plasmid vectors or 30 nM of 
siRNAs were placed in the cuvette. pMaxGFP® (Lonza) 
was used to evaluate transfection efficiency. Nucleofection 
was done using program V-001 or U-015 on the Shuttle 
System. After nucleofection, the content of each cuvette 
was dispersed as rapidly as possible with 500 μl of the 
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pre-equilibrated culture medium and transferred into 
a 12-wells plate. Twenty-four hours after transfection 
experiments were performed. 
Luciferase reporter assays
100 ng of luciferase plasmids (psiCHECKTM-2) 
encoding wild-type or mutant 3’UTR of USP7 were 
co-transfected with synthetic pre-miRNA (hsa-miR-
338-3p, AMBIONPM10716) or pre-miRNA (has-miR-
181b-3p, AMBIONPM20327) in HEK 293T cells with 
Lipofectamine 2000 (Invitrogen) and the luciferase assay 
was performed with the Dual-Luciferase Reporter Assay 
System (Promega). Luminescence was measured with the 
“Dual Glow” protocol of the GloMax MULTI Detection 
System (Promega). The luciferase signal obtained 
from Renilla was normalized against Firefly luciferase 
intraplasmid control. The USP7 sensor vector (containing 
the single miR-338-3p and miR-181b MRE) was obtained 
by annealing the following oligonucleotides:
USP7SENSOR_WT_338-3p_FW: 
tcgagCCTGTATATTGCCTTTTTGCTGGAAAAaagcttgc 
USP7SENSOR_WT_338-3p_RV:
 ggcc gcaagcttTTTTCCAGCAAAAAGGCAATATA 
CAGGc
USP7SENSOR_WT_181b_FW:
tcgagTATAAAAATTATAATTCAGTGAGcatatggc 
USP7SENSOR_WT_181b_RV: 
ggccgccatatgCTCACTGAATTATAATTTTTATAc
The same procedure was used to generate the 
mutated sensor using the following oligonucleotides:
USP7SENSOR_MUT_338-3p_FW:
 tcgagCCTGTATATTGCCTTTTCTAC 
TTCAAAaagcttgc 
USP7SENSOR_MUT_338-3p_RV:
 gg ccgcaagcttTTTGAAGTAGAAAAGGCA 
ATATACAGGc
USP7SENSOR_MUT_181b_FW:
tcgagTATAAAAATTATAATGACTGTCGcatatggc 
USP7SENSOR_MUT_181b_RV: 
ggccgccatatgCGACAGTCATTATAATTTTTATAc
Antibodies and inhibitors
PTEN (#9188S), Phospho-Serine (#9631S), 
GAPDH (#5174), Cleaved Caspase-3 (#9661), NOXA 
(#14766), BAX (#2772), PUMA (#4976) and HSP90 
(#4874) were from Cell Signaling Technologies; PTEN 
(#sc133197), CK2 (#sc12738), Laminin (#sc-6216), 
USP7 (#sc30164), P21(#sc817), MDM2 (#sc965) were 
from Santa Cruz; Anti-Ubiquitin was from BD Pharmigen 
(#550944); GFP (A6455) was from Invitrogen; Tubulin 
(#T5201), Actin (#A5060) were from Sigma-Aldrich. 
HMG14 was from Abcam (#ab5212); pSer18 USP7 
(#ABC225) was from Millipore. USP7 inhibitor (P5091), 
Idelalisib (CAL-101, GS-1101) and CK2 inhibitor (TBB) 
were from Selleckchem and Sigma-Aldrich, respectively.
Cell lysis, western blot assay and 
immunoprecipitation
 For cytosol/nuclear fractionation cell pellets were 
resuspended in hypotonic lysis buffer (10 mM Hepes 
pH 7.9, 10 mM KCl, 0.1 mM EDTA pH 8.0, protease 
inhibitors and phosphatase inhibitors) and incubated on 
ice for 20 minutes. After the addition of NP40, samples 
were centrifuged at 1200×g for 5 minutes and cytosolic 
extracts were recovered. Nuclear pellets were resuspended 
in nuclear extraction buffer (20 mM Hepes pH 7.9, 0.4M 
NaCl, 1 mM EDTA pH 8.0, protease and phosphatase 
inhibitors). The lysates were subjected to alternative 
vortex mixing and ice-cooling, and after centrifugation 
the nuclear extracts were collected. Immunoprecipitation 
was performed using whole-cell lysates. Proteins were 
extracted with lysis buffer containing 150 mM NaCl, 1 
mM EDTA, 50 mM Hepes (pH 7.5), 1% Triton X-100 and 
10% glycerol. Then lysates were incubated with antibodies 
overnight at 4°C on a rotator. Protein A/G-PLUS-Agarose 
beads (Santa Cruz #2003) were added and incubated 
for 2 hours at 4°C with rotation. Beads bound with 
immunoreactive complexes were washed four times with 
cold lysis buffer. Immunoprecipitated complexes were 
boiled for 5 min and subsequently ran using SDS-PAGE 
on 8% or 6% gels and transferred onto nitrocellulose 
filters. Immunoblots were then probed overnight at 4°C 
with specific antibodies in PBS-0,1% tween-1% BSA and 
protein detection was performed by using peroxidase-
conjugated secondary antibodies and chemiluminescence 
reagent (BIORAD, #170-5060). A similar protein running 
and transfer procedure was used for Western blotting. 
Kinase assay
In vitro kinase assay was performed with 
immunoprecipitated CK2 kinase and purified His-GST-
USP7 (Invitrogen, #11681-H20BL-50), in basal conditions 
or in presence of CK2 inhibitor TBB (60 μM). After 30 
minutes at 37°C, reaction was stopped at 95°C and 
Western Blot was performed. 
Gene expression analysis
RNA was extracted from cells using TRIzol 
(Invitrogen). 1 μg of total RNA was used for reverse 
transcription. Real-time PCR was performed with iQ 
SYBR Green (Bio-Rad). Primers used were: 
hUSP7_TOT_FW: 
5’-CGCTGGGGAACATGGCTTAC-3’ 
hUSP7_TOT_RV: 
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5’-TTGGTCCGTCTGAGGGTCAT-3’
hUSP7_ISO1_FW:5’-CCGAGGACATGGAGATG 
GAAG-3’ 
hUSP7_ISO1_RV: 5’-CGCCAACTGGTGTCAT 
CCTC-3’ 
hUSP7_ISO3_FW:5’-TGCCAAAAGTTCAGCCT 
CCAT-3’
hUSP7_ISO3_RV: 5’-GGCTAAGGACCGACT 
CACTCA-3’ 
hHuPO FW: 5’-GCTTCCTGGAGGGTGTCC-3’
hHuPO RV: 5’-GGACTCGTTTGTACCCGTTG-3’
Real-time PCR parameters were: cycle 1, 95°C-
3 minutes; cycle 2, 95°C-15 seconds, 60°C-30 seconds 
for 40 cycles. For p21 quantification specific assays 
with on-demand primer/probe kits (Hs00355782_m1 for 
p21) (Applied Biosystems, Foster City, CA, USA) were 
conducted according to the manufacturer’s instructions. 
The 2-ΔΔCT method was used to analyze the data. hHuPO 
was used to normalize the results.  
Gene and miRNA expression data analysis
 Expression analysis of USP7 was assessed in a 
panel of 217 CLL relative to 12 control samples available 
at GEO (GSE51528) [35]. Samples were assayed on 
Affymetrix Human Gene 1.0 ST and have been normalized 
by the RMA algorithm. Differential Expression analysis 
has been performed using GEO2R tool. The correlation 
between the gene USP7 and its putative targeting miRNAs 
was evaluated on 210 matching samples. miRNAs were 
assayed on Agilent-019118 Human miRNA Microarray 
2.0 G4470B available at GEO website (GSE51527) [35]. 
A log2 transformation has been applied to the miRNAs 
expression levels. The Pearson coefficient has been used 
to evaluate the correlation between the USP7 gene and 
miR-338-3p or miR181b. 
Immunofluorescence and immunohistochemistry
Immunofluorescence was performed as previously 
described [20]. Immunohistochemistry experiments were 
performed on formalin-fixed, paraffin-embedded tissues 
from n = 5 patients, as previously reported [60].
Cell proliferation assay, cell-cycle analysis and 
assessment of apoptosis
For proliferation, cells were seeded in 96-well 
plates at a density of 1.5×103 cells/well. Proliferation 
was evaluated by CellTiter-Glo (Promega) following 
the manufacturer's instructions. Cell-cycle analysis and 
apoptosis were performed as previously described [61].
Anchorage-independent cell-growth assay
Cells were suspended in 0.45% type VII low-
melting agarose in 10% IMDM at a density of 5×103 cells/
well and plated on a layer of 0.9% type VII low-melting 
agarose in 10% IMDM in 6-well plates, then cultured at 
37°C with 5% CO2. After 2 weeks, colonies were counted 
and images were acquired at 5x magnification.
Statistical analysis
Two-sided Student’s t-test or two-way ANOVA 
with Bonferroni post-test were calculated using GraphPad 
Prism v5.0d (GraphPad Software). P-values < 0.05 were 
considered statistically significant. *P < 0.05; **P < 0.01; 
***P < 0.001; ****P < 0.0001. All mean values (± SEM) 
are from 3 independent experiments.
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